CrystagenvsThymulin

Crystagen is a short Khavinson tripeptide (Glu-Asp-Pro) positioned as the immune and thymus-targeted bioregulator within the wider Khavinson peptide family. The proposed mechanism follows the standard family framework: short peptides interact with gene promoter sequences in thymic and lymphocyte cell nuclei, modulating expression of genes involved in T cell maturation, cytokine production, and broader immune regulation.

Proposed effects include support for thymic function — particularly relevant given the well-documented age-related thymic involution that contributes to immunosenescence in older adults — alongside modulation of lymphocyte chromatin organisation and immune cell maturation pathways. Russian research has reported crystagen-induced improvements in lymphocyte counts, T helper cell function, and clinical recovery from infections in elderly populations and in patients recovering from immunosuppressive treatments. The peptide is often used alongside thymalin (a related thymic peptide preparation also in this database) as part of broader Khavinson immune-support protocols.

As with the rest of the Khavinson family, the efficacy evidence base sits within Russian gerontology and immunology research with limited independent Western validation. Crystagen is not validated as a treatment for primary immunodeficiency, HIV-related immune dysfunction, or other formally diagnosed immune conditions, and should not displace evidence-based immune therapy. The brief plasma half-life (around 30 minutes) reflects the proposed model of transient signalling triggering longer-lasting transcriptional changes in immune cell populations.

Thymulin (also known as facteur thymique sérique, FTS) is a nonapeptide (Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) that is unique among thymic hormones in requiring a zinc ion for biological activity. The zinc ion is coordinated by the asparagine (position 9), serine (position 4), and the N-terminal glutamic acid, creating a metallopeptide complex where the zinc is essential for the correct three-dimensional conformation needed for receptor binding. Without zinc, thymulin is biologically inactive — this zinc dependency has important implications for immune function in zinc-deficient individuals.

Thymulin is produced exclusively by thymic epithelial cells and is the only thymic hormone that is truly thymus-specific — its serum levels become undetectable after thymectomy (surgical thymus removal). It binds to high-affinity receptors on T-cell precursors (thymocytes) and mature T cells, promoting several key aspects of T-cell biology. It induces the expression of T-cell differentiation markers (CD2, CD3, CD4, CD8), driving immature thymocytes through the stages of T-cell maturation. It enhances the cytotoxic function of CD8+ T cells and the helper function of CD4+ T cells. It modulates the balance between T-helper and T-suppressor (regulatory) cell populations, promoting appropriate immune regulation.

Thymulin also modulates cytokine production — it promotes IL-2 secretion (essential for T-cell proliferation and the generation of effector T cells), enhances IFN-γ production (important for Th1 cellular immunity), and influences the balance of pro-inflammatory versus anti-inflammatory cytokines. Serum thymulin levels peak around puberty and decline progressively with age, becoming virtually undetectable by age 60 — mirroring the age-related involution of the thymus gland. This decline correlates closely with immunosenescence markers: reduced naive T-cell output, skewed CD4/CD8 ratios, impaired vaccine responses, and increased susceptibility to infections and cancer. Zinc supplementation alone can partially restore thymulin activity in zinc-deficient elderly individuals, highlighting the clinical importance of the zinc-thymulin interaction.